Products for Research Use Only
RegisterLogin

Ruboxistaurin

CAT: 0804-HY-10195-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10195-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor (Ki=2 nM) . Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC50 of 5.9 nM[1][2].
CAS Number
169939-94-0
Product Name Alternative
LY333531
UNSPSC
12352005
Target
PKC
Type
Reference compound
Related Pathways
Epigenetics; TGF-beta/Smad
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ruboxistaurin.html
Purity
99.48
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |THF : < 1 mg/mL (ultrasonic)
Smiles
O=C1NC(C(C2=CN(C3=CC=CC=C32)CCO[C@H](CN(C)C)CC4)=C1C5=CN4C6=CC=CC=C56)=O
Molecular Formula
C28H28N4O3
Molecular Weight
468.55
References & Citations
[1]Jirousek MR, et al. (S) -13-[ (dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3 (2H) -d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39 (14) :2664-2671.|[2]Ruboxistaurin: LY 333531. Drugs R D. 2007;8 (3) :193-199.|[3]Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1 (6) :929-35.|[4]Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41 (9) :2702-6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PKCα; PKCβ; PKCγ; PKCδ; PKCε; PKCη
Citation 01
Acta Pharm Sin B. 2023 Mar;13 (3) :1053-1070.|bioRxiv. 2024 June 29.|FASEB J. 2024 Mar 31;38 (6) :e23564.|In Vitro Cell Dev Biol Anim. 2025 Jun;61 (6) :635-643.|Rheumatology (Oxford) . 2025 Aug 13:keaf437.|Trop J Pharm Res. 2022; 21 (12) : 2508.|ACS Omega. 2020 Oct 12;5 (41) :26551-26561.|Biosci Rep. 2018 Sep 7;38 (5) :BSR20171459.|Cell Biosci. 2021 Feb 8;11 (1) :32.|Diabetes Metab Syndr Obes. 2019 Nov 4;12:2289-2302.|Endocrinology. 2018 May 1;159 (5) :2253-2263.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.

Alternative Products

CatalogName
BA4959-5.1Ruboxistaurin
SHA05059-01Ruboxistaurin mesylate
FR27768-01Ruboxistaurin hydrochloride
326958Ruboxistaurin HCl
CS-O-62272Ruboxistaurin-d5
MBS385080-01Ruboxistaurin (LY333531)
MBS130648-01Ruboxistaurin?LY333531)
MBS5812533Ruboxistaurin mesylate monohydrate
A12399-100Ruboxistaurin (LY333531) 100mg

Popular Products